{"pmid":32392072,"title":"Novel Coronavirus Polymerase and Nucleotidyl-transferase Structures: Potential to Target New Outbreaks.","text":["Novel Coronavirus Polymerase and Nucleotidyl-transferase Structures: Potential to Target New Outbreaks.","The pandemic outbreak of a new coronavirus (CoV), SARS-CoV-2, has captured the world's attention, demonstrating that CoVs induce a continuous global threat. As this is a highly contagious virus, it is imperative to understand RNA-dependent-RNA-polymerase (RdRp), the key component in virus replication. Although the SARS-CoV-2 genome shares 80% sequence identity with severe acute respiratory syndrome (SARS) CoV, their RdRps and nucleotidyl-transferases (NiRAN) share 98.1% and 93.2% identity, respectively. Sequence alignment of six coronaviruses demonstrated higher identity among their RdRps (60.9-98.1%) and lower identity among their Spike proteins (27-77%). Thus, a 3D structural model of RdRp, NiRAN, nsp7 and nsp8 of SARS-CoV-2 was generated by modelling starting from the SARS counterpart structures. Furthermore, we demonstrate the binding poses of three viral RdRp inhibitors: Galidesivir, Favipiravir, and Penciclovir, which was recently reported to have clinical significance for SARS-CoV-2. The network of interactions established by these drug molecules affirm their efficacy to inhibit viral RNA replication and provide an insight into their structure-based rational optimization for SARS-CoV-2 inhibition.","J Phys Chem Lett","Zhang, Wenfa","Stephen, Preyesh","Theriault, Jean-Francois","Wang, Ruixuan","Lin, Sheng-Xiang","32392072"],"abstract":["The pandemic outbreak of a new coronavirus (CoV), SARS-CoV-2, has captured the world's attention, demonstrating that CoVs induce a continuous global threat. As this is a highly contagious virus, it is imperative to understand RNA-dependent-RNA-polymerase (RdRp), the key component in virus replication. Although the SARS-CoV-2 genome shares 80% sequence identity with severe acute respiratory syndrome (SARS) CoV, their RdRps and nucleotidyl-transferases (NiRAN) share 98.1% and 93.2% identity, respectively. Sequence alignment of six coronaviruses demonstrated higher identity among their RdRps (60.9-98.1%) and lower identity among their Spike proteins (27-77%). Thus, a 3D structural model of RdRp, NiRAN, nsp7 and nsp8 of SARS-CoV-2 was generated by modelling starting from the SARS counterpart structures. Furthermore, we demonstrate the binding poses of three viral RdRp inhibitors: Galidesivir, Favipiravir, and Penciclovir, which was recently reported to have clinical significance for SARS-CoV-2. The network of interactions established by these drug molecules affirm their efficacy to inhibit viral RNA replication and provide an insight into their structure-based rational optimization for SARS-CoV-2 inhibition."],"journal":"J Phys Chem Lett","authors":["Zhang, Wenfa","Stephen, Preyesh","Theriault, Jean-Francois","Wang, Ruixuan","Lin, Sheng-Xiang"],"date":"2020-05-12T11:00:00Z","year":2020,"_id":"32392072","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1021/acs.jpclett.0c00571","locations":["RdRp","NiRAN"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666528580046159872,"score":9.490897,"similar":[{"pmid":32306854,"pmcid":"PMC7189410","title":"Novel guanosine derivatives against MERS CoV polymerase: An in silico perspective.","text":["Novel guanosine derivatives against MERS CoV polymerase: An in silico perspective.","The Middle East Respiratory Syndrome Coronavirus (MERS CoV), also termed camel flu, is a new viral infection that first reported in the year 2012 in the Middle East region and further spread during the last seven years. MERS CoV is characterized by its high mortality rate among different human coronaviruses. MERS CoV polymerase shares more than 20% sequence identity with the Hepatitis C Virus (HCV) Non-structural 5b (NS5b) RNA dependent RNA polymerase (RdRp). Despite the low sequence identity, the active site is conserved between the two proteins, with two consecutive aspartates that are crucial in the nucleotide transfer reaction. In this study, seven nucleotide inhibitors have been tested against MERS CoV RdRp using molecular modeling and docking simulations, from which four are novel compounds. Molecular Dynamics Simulation for 260 nanoseconds is performed on the MERS CoV RdRp model to test the effect of protein dynamics on the binding affinities to the tested nucleotide inhibitors. Results support the hypothesis of using the anti-polymerases (Anti-HCV drugs) against MERS CoV RdRp as a potent candidates. Besides four novel compounds are suggested as a seed for high performance inhibitors against MERS CoV RdRp.Communicated by Ramaswamy H. Sarma.","J Biomol Struct Dyn","Elfiky, Abdo A","Azzam, Eman B","32306854"],"abstract":["The Middle East Respiratory Syndrome Coronavirus (MERS CoV), also termed camel flu, is a new viral infection that first reported in the year 2012 in the Middle East region and further spread during the last seven years. MERS CoV is characterized by its high mortality rate among different human coronaviruses. MERS CoV polymerase shares more than 20% sequence identity with the Hepatitis C Virus (HCV) Non-structural 5b (NS5b) RNA dependent RNA polymerase (RdRp). Despite the low sequence identity, the active site is conserved between the two proteins, with two consecutive aspartates that are crucial in the nucleotide transfer reaction. In this study, seven nucleotide inhibitors have been tested against MERS CoV RdRp using molecular modeling and docking simulations, from which four are novel compounds. Molecular Dynamics Simulation for 260 nanoseconds is performed on the MERS CoV RdRp model to test the effect of protein dynamics on the binding affinities to the tested nucleotide inhibitors. Results support the hypothesis of using the anti-polymerases (Anti-HCV drugs) against MERS CoV RdRp as a potent candidates. Besides four novel compounds are suggested as a seed for high performance inhibitors against MERS CoV RdRp.Communicated by Ramaswamy H. Sarma."],"journal":"J Biomol Struct Dyn","authors":["Elfiky, Abdo A","Azzam, Eman B"],"date":"2020-04-21T11:00:00Z","year":2020,"_id":"32306854","source":"PubMed","week":"202017|Apr 20 - Apr 26","doi":"10.1080/07391102.2020.1758789","keywords":["hcv ns5b rdrp","mers cov","molecular docking","molecular dynamics simulation","polymerase"],"e_drugs":["Aspartic Acid","Guanosine"],"topics":["Mechanism"],"weight":1,"_version_":1666138491287764992,"score":388.54617},{"pmid":32284326,"title":"Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency.","text":["Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency.","Effective treatments for coronavirus disease 2019 (COVID-19) are urgently needed to control this current pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Replication of SARS-CoV-2 depends on the viral RNA-dependent RNA polymerase (RdRp), which is the likely target of the investigational nucleotide analogue remdesivir (RDV). RDV shows broad-spectrum antiviral activity against RNA viruses, and previous studies with RdRps from Ebola virus (EBOV) and Middle East respiratory syndrome coronavirus (MERS-CoV) have revealed that delayed chain-termination is RDV's plausible mechanism of action. Here, we expressed and purified active SARS-CoV-2 RdRp composed of the non-structural proteins nsp8 and nsp12. Enzyme kinetics indicated that this RdRp efficiently incorporates the active triphosphate form of RDV (RDV-TP) into RNA. Incorporation of RDV-TP at position i caused termination of RNA synthesis at position i+3. We obtained almost identical results with SARS-CoV, MERS-CoV, and SARS-CoV-2 RdRps. A unique property of RDV-TP is its high selectivity over incorporation of its natural nucleotide counterpart ATP. In this regard, the triphosphate forms of 2'-C-methylated compounds, including sofosbuvir, approved for the management of hepatitis C virus infection, and the broad-acting antivirals favipiravir and ribavirin, exhibited significant deficits. Furthermore, we provide evidence for the target specificity of RDV, as RDV-TP was less efficiently incorporated by the distantly related Lassa virus RdRp, and termination of RNA synthesis was not observed. These results collectively provide a unifying, refined mechanism of RDV-mediated RNA synthesis inhibition in coronaviruses and define this nucleotide analogue as a direct-acting antiviral (DAA).","J Biol Chem","Gordon, Calvin J","Tchesnokov, Egor P","Woolner, Emma","Perry, Jason K","Feng, Joy Y","Porter, Danielle P","Gotte, Matthias","32284326"],"abstract":["Effective treatments for coronavirus disease 2019 (COVID-19) are urgently needed to control this current pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Replication of SARS-CoV-2 depends on the viral RNA-dependent RNA polymerase (RdRp), which is the likely target of the investigational nucleotide analogue remdesivir (RDV). RDV shows broad-spectrum antiviral activity against RNA viruses, and previous studies with RdRps from Ebola virus (EBOV) and Middle East respiratory syndrome coronavirus (MERS-CoV) have revealed that delayed chain-termination is RDV's plausible mechanism of action. Here, we expressed and purified active SARS-CoV-2 RdRp composed of the non-structural proteins nsp8 and nsp12. Enzyme kinetics indicated that this RdRp efficiently incorporates the active triphosphate form of RDV (RDV-TP) into RNA. Incorporation of RDV-TP at position i caused termination of RNA synthesis at position i+3. We obtained almost identical results with SARS-CoV, MERS-CoV, and SARS-CoV-2 RdRps. A unique property of RDV-TP is its high selectivity over incorporation of its natural nucleotide counterpart ATP. In this regard, the triphosphate forms of 2'-C-methylated compounds, including sofosbuvir, approved for the management of hepatitis C virus infection, and the broad-acting antivirals favipiravir and ribavirin, exhibited significant deficits. Furthermore, we provide evidence for the target specificity of RDV, as RDV-TP was less efficiently incorporated by the distantly related Lassa virus RdRp, and termination of RNA synthesis was not observed. These results collectively provide a unifying, refined mechanism of RDV-mediated RNA synthesis inhibition in coronaviruses and define this nucleotide analogue as a direct-acting antiviral (DAA)."],"journal":"J Biol Chem","authors":["Gordon, Calvin J","Tchesnokov, Egor P","Woolner, Emma","Perry, Jason K","Feng, Joy Y","Porter, Danielle P","Gotte, Matthias"],"date":"2020-04-15T11:00:00Z","year":2020,"_id":"32284326","source":"PubMed","week":"202016|Apr 13 - Apr 19","doi":"10.1074/jbc.RA120.013679","keywords":["rna polymerase","drug action","drug development","drug discovery","plus-stranded rna virus"],"e_drugs":["remdesivir","triphosphoric acid","Sofosbuvir","Ribavirin","Adenosine Triphosphate","favipiravir"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666138491332853760,"score":379.81805},{"pmid":32438371,"title":"Structure of replicating SARS-CoV-2 polymerase.","text":["Structure of replicating SARS-CoV-2 polymerase.","The coronavirus SARS-CoV-2 uses an RNA-dependent RNA polymerase (RdRp) for the replication of its genome and the transcription of its genes(1-3). Here we present the cryo-electron microscopic structure of the SARS-CoV-2 RdRp in active form, mimicking the replicating enzyme. The structure comprises the viral proteins nsp12, nsp8, and nsp7, and over two turns of RNA template-product duplex. The active site cleft of nsp12 binds the first turn of RNA and mediates RdRp activity with conserved residues. Two copies of nsp8 bind to opposite sides of the cleft and position the second turn of RNA. Long helical extensions in nsp8 protrude along exiting RNA, forming positively charged 'sliding poles'. These sliding poles can account for the known processivity of the RdRp that is required for replicating the long coronavirus genome(3). Our results enable a detailed analysis of the inhibitory mechanisms that underlie the antiviral activity of substances such as remdesivir, a drug for the treatment of coronavirus disease 2019 (COVID-19)(4).","Nature","Hillen, Hauke S","Kokic, Goran","Farnung, Lucas","Dienemann, Christian","Tegunov, Dimitry","Cramer, Patrick","32438371"],"abstract":["The coronavirus SARS-CoV-2 uses an RNA-dependent RNA polymerase (RdRp) for the replication of its genome and the transcription of its genes(1-3). Here we present the cryo-electron microscopic structure of the SARS-CoV-2 RdRp in active form, mimicking the replicating enzyme. The structure comprises the viral proteins nsp12, nsp8, and nsp7, and over two turns of RNA template-product duplex. The active site cleft of nsp12 binds the first turn of RNA and mediates RdRp activity with conserved residues. Two copies of nsp8 bind to opposite sides of the cleft and position the second turn of RNA. Long helical extensions in nsp8 protrude along exiting RNA, forming positively charged 'sliding poles'. These sliding poles can account for the known processivity of the RdRp that is required for replicating the long coronavirus genome(3). Our results enable a detailed analysis of the inhibitory mechanisms that underlie the antiviral activity of substances such as remdesivir, a drug for the treatment of coronavirus disease 2019 (COVID-19)(4)."],"journal":"Nature","authors":["Hillen, Hauke S","Kokic, Goran","Farnung, Lucas","Dienemann, Christian","Tegunov, Dimitry","Cramer, Patrick"],"date":"2020-05-22T11:00:00Z","year":2020,"_id":"32438371","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1038/s41586-020-2368-8","e_drugs":["remdesivir"],"topics":["Mechanism","Treatment"],"weight":1,"_version_":1667521393648992256,"score":367.52985},{"pmid":32094225,"pmcid":"PMC7152756","title":"The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus.","text":["The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus.","Antiviral drugs for managing infections with human coronaviruses are not yet approved, posing a serious challenge to current global efforts aimed at containing the outbreak of severe acute respiratory syndrome-coronavirus 2 (CoV-2). Remdesivir (RDV) is an investigational compound with a broad spectrum of antiviral activities against RNA viruses, including severe acute respiratory syndrome-CoV and Middle East respiratory syndrome (MERS-CoV). RDV is a nucleotide analog inhibitor of RNA-dependent RNA polymerases (RdRps). Here, we co-expressed the MERS-CoV nonstructural proteins nsp5, nsp7, nsp8, and nsp12 (RdRp) in insect cells as a part a polyprotein to study the mechanism of inhibition of MERS-CoV RdRp by RDV. We initially demonstrated that nsp8 and nsp12 form an active complex. The triphosphate form of the inhibitor (RDV-TP) competes with its natural counterpart ATP. Of note, the selectivity value for RDV-TP obtained here with a steady-state approach suggests that it is more efficiently incorporated than ATP and two other nucleotide analogs. Once incorporated at position i, the inhibitor caused RNA synthesis arrest at position i + 3. Hence, the likely mechanism of action is delayed RNA chain termination. The additional three nucleotides may protect the inhibitor from excision by the viral 3'-5' exonuclease activity. Together, these results help to explain the high potency of RDV against RNA viruses in cell-based assays.","J Biol Chem","Gordon, Calvin J","Tchesnokov, Egor P","Feng, Joy Y","Porter, Danielle P","Gotte, Matthias","32094225"],"abstract":["Antiviral drugs for managing infections with human coronaviruses are not yet approved, posing a serious challenge to current global efforts aimed at containing the outbreak of severe acute respiratory syndrome-coronavirus 2 (CoV-2). Remdesivir (RDV) is an investigational compound with a broad spectrum of antiviral activities against RNA viruses, including severe acute respiratory syndrome-CoV and Middle East respiratory syndrome (MERS-CoV). RDV is a nucleotide analog inhibitor of RNA-dependent RNA polymerases (RdRps). Here, we co-expressed the MERS-CoV nonstructural proteins nsp5, nsp7, nsp8, and nsp12 (RdRp) in insect cells as a part a polyprotein to study the mechanism of inhibition of MERS-CoV RdRp by RDV. We initially demonstrated that nsp8 and nsp12 form an active complex. The triphosphate form of the inhibitor (RDV-TP) competes with its natural counterpart ATP. Of note, the selectivity value for RDV-TP obtained here with a steady-state approach suggests that it is more efficiently incorporated than ATP and two other nucleotide analogs. Once incorporated at position i, the inhibitor caused RNA synthesis arrest at position i + 3. Hence, the likely mechanism of action is delayed RNA chain termination. The additional three nucleotides may protect the inhibitor from excision by the viral 3'-5' exonuclease activity. Together, these results help to explain the high potency of RDV against RNA viruses in cell-based assays."],"journal":"J Biol Chem","authors":["Gordon, Calvin J","Tchesnokov, Egor P","Feng, Joy Y","Porter, Danielle P","Gotte, Matthias"],"date":"2020-02-26T11:00:00Z","year":2020,"_id":"32094225","source":"PubMed","week":"20209|Feb 24 - Mar 01","doi":"10.1074/jbc.AC120.013056","keywords":["ebola virus (ebov)","middle east respiratory syndrome coronavirus (mers-cov)","rna chain termination","rna-dependent rna polymerase (rdrp)","sars-cov-2","antiviral drug","coronavirus","drug development","enzyme inhibitor","nucleoside/nucleotide analog","plus-stranded rna virus","positive-sense rna virus","remdesivir","viral polymerase","viral replicase"],"e_drugs":["remdesivir","triphosphoric acid","Adenosine Triphosphate"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666138490805420032,"score":351.46832},{"pmid":32277040,"pmcid":"PMC7164392","title":"Structure of the RNA-dependent RNA polymerase from COVID-19 virus.","text":["Structure of the RNA-dependent RNA polymerase from COVID-19 virus.","A novel coronavirus (COVID-19 virus) outbreak has caused a global pandemic resulting in tens of thousands of infections and thousands of deaths worldwide. The RNA-dependent RNA polymerase (RdRp, also named nsp12) is the central component of coronaviral replication/transcription machinery and appears to be a primary target for the antiviral drug, remdesivir. We report the cryo-EM structure of COVID-19 virus full-length nsp12 in complex with cofactors nsp7 and nsp8 at 2.9-A resolution. In addition to the conserved architecture of the polymerase core of the viral polymerase family, nsp12 possesses a newly identified beta-hairpin domain at its N terminus. A comparative analysis model shows how remdesivir binds to this polymerase. The structure provides a basis for the design of new antiviral therapeutics targeting viral RdRp.","Science","Gao, Yan","Yan, Liming","Huang, Yucen","Liu, Fengjiang","Zhao, Yao","Cao, Lin","Wang, Tao","Sun, Qianqian","Ming, Zhenhua","Zhang, Lianqi","Ge, Ji","Zheng, Litao","Zhang, Ying","Wang, Haofeng","Zhu, Yan","Zhu, Chen","Hu, Tianyu","Hua, Tian","Zhang, Bing","Yang, Xiuna","Li, Jun","Yang, Haitao","Liu, Zhijie","Xu, Wenqing","Guddat, Luke W","Wang, Quan","Lou, Zhiyong","Rao, Zihe","32277040"],"abstract":["A novel coronavirus (COVID-19 virus) outbreak has caused a global pandemic resulting in tens of thousands of infections and thousands of deaths worldwide. The RNA-dependent RNA polymerase (RdRp, also named nsp12) is the central component of coronaviral replication/transcription machinery and appears to be a primary target for the antiviral drug, remdesivir. We report the cryo-EM structure of COVID-19 virus full-length nsp12 in complex with cofactors nsp7 and nsp8 at 2.9-A resolution. In addition to the conserved architecture of the polymerase core of the viral polymerase family, nsp12 possesses a newly identified beta-hairpin domain at its N terminus. A comparative analysis model shows how remdesivir binds to this polymerase. The structure provides a basis for the design of new antiviral therapeutics targeting viral RdRp."],"journal":"Science","authors":["Gao, Yan","Yan, Liming","Huang, Yucen","Liu, Fengjiang","Zhao, Yao","Cao, Lin","Wang, Tao","Sun, Qianqian","Ming, Zhenhua","Zhang, Lianqi","Ge, Ji","Zheng, Litao","Zhang, Ying","Wang, Haofeng","Zhu, Yan","Zhu, Chen","Hu, Tianyu","Hua, Tian","Zhang, Bing","Yang, Xiuna","Li, Jun","Yang, Haitao","Liu, Zhijie","Xu, Wenqing","Guddat, Luke W","Wang, Quan","Lou, Zhiyong","Rao, Zihe"],"date":"2020-04-12T11:00:00Z","year":2020,"_id":"32277040","source":"PubMed","week":"202015|Apr 06 - Apr 12","doi":"10.1126/science.abb7498","e_drugs":["remdesivir"],"topics":["Mechanism","Treatment"],"weight":1,"_version_":1666138491615969280,"score":340.14334}]}